Volker Laux

1.9k total citations
39 papers, 1.4k citations indexed

About

Volker Laux is a scholar working on Hematology, Cardiology and Cardiovascular Medicine and Internal Medicine. According to data from OpenAlex, Volker Laux has authored 39 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 18 papers in Cardiology and Cardiovascular Medicine and 11 papers in Internal Medicine. Recurrent topics in Volker Laux's work include Blood Coagulation and Thrombosis Mechanisms (20 papers), Atrial Fibrillation Management and Outcomes (13 papers) and Venous Thromboembolism Diagnosis and Management (11 papers). Volker Laux is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (20 papers), Atrial Fibrillation Management and Outcomes (13 papers) and Venous Thromboembolism Diagnosis and Management (11 papers). Volker Laux collaborates with scholars based in Germany, United States and Austria. Volker Laux's co-authors include Elisabeth Perzborn, Stefan Heitmeier, Dagmar Kubitza, Susanne Roehrig, Alexander Straub, Wolfgang Mueck, Ulf Buetehorn, Frank Misselwitz, Christoph Gerdes and M. Lorenz and has published in prestigious journals such as Blood, PLoS ONE and Journal of Medicinal Chemistry.

In The Last Decade

Volker Laux

38 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Volker Laux Germany	21	727	499	434	210	168	39	1.4k
Susanne Roehrig Germany	12	861 1.2×	638 1.3×	434 1.0×	238 1.1×	144 0.9×	12	1.5k
Athiwat Hutchaleelaha United States	20	761 1.0×	565 1.1×	458 1.1×	225 1.1×	103 0.6×	38	1.7k
Margareta Elg Sweden	16	698 1.0×	581 1.2×	475 1.1×	135 0.6×	286 1.7×	32	1.3k
E. Seifried Germany	18	367 0.5×	242 0.5×	316 0.7×	251 1.2×	153 0.9×	44	1.9k
Sven Nylander Sweden	26	1.4k 2.0×	569 1.1×	415 1.0×	431 2.1×	544 3.2×	52	2.6k
Uma Sinha United States	29	1.2k 1.6×	812 1.6×	743 1.7×	746 3.6×	242 1.4×	109	2.9k
Erika Gyzander Sweden	14	378 0.5×	288 0.6×	456 1.1×	230 1.1×	224 1.3×	20	1.2k
Mojca Stegnar Slovenia	20	284 0.4×	234 0.5×	321 0.7×	226 1.1×	176 1.0×	75	1.3k
Christer Mattsson Sweden	24	570 0.8×	463 0.9×	671 1.5×	204 1.0×	259 1.5×	49	1.5k
Karl‐Heinz Schlemmer Germany	10	357 0.5×	167 0.3×	144 0.3×	277 1.3×	92 0.5×	17	1.3k

Countries citing papers authored by Volker Laux

Since Specialization

Citations

This map shows the geographic impact of Volker Laux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Volker Laux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Volker Laux more than expected).

Fields of papers citing papers by Volker Laux

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Volker Laux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Volker Laux. The network helps show where Volker Laux may publish in the future.

Co-authorship network of co-authors of Volker Laux

This figure shows the co-authorship network connecting the top 25 collaborators of Volker Laux. A scholar is included among the top collaborators of Volker Laux based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Volker Laux. Volker Laux is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Knethen, Andreas von, Ulrike Heinicke, Volker Laux, et al.. (2022). Antioxidants as Therapeutic Agents in Acute Respiratory Distress Syndrome (ARDS) Treatment—From Mice to Men. Biomedicines. 10(1). 98–98. 16 indexed citations

Ulshöfer, Thomas, Marina Henke, Denisa Bojková, et al.. (2021). Characterization of ACE Inhibitors and AT1R Antagonists with Regard to Their Effect on ACE2 Expression and Infection with SARS-CoV-2 Using a Caco-2 Cell Model. Life. 11(8). 810–810. 9 indexed citations

López, Mercedes, et al.. (2020). The dual FXa/thrombin inhibitor SATI prevents fibrin and platelet deposition in hypercoagulant rats. Thrombosis Research. 193. 15–21.

Cate, Vincent ten, Thomas Koeck, Marina Panova‐Noeva, et al.. (2019). A prospective cohort study to identify and evaluate endotypes of venous thromboembolism: Rationale and design of the Genotyping and Molecular Phenotyping in Venous ThromboEmbolism project (GMP-VTE). Thrombosis Research. 181. 84–91. 11 indexed citations

Visser, Mayken, René van Oerle, Hugo Ten Cate, et al.. (2019). Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX. Arteriosclerosis Thrombosis and Vascular Biology. 40(1). 103–111. 43 indexed citations

Schöchl, Herbert, Martijn van Griensven, Stefan Heitmeier, et al.. (2017). Dual inhibition of thrombin and activated factor X attenuates disseminated intravascular coagulation and protects organ function in a baboon model of severe Gram-negative sepsis. Critical Care. 21(1). 51–51. 12 indexed citations

Ponschab, Martin, Martijn van Griensven, Stefan Heitmeier, et al.. (2016). Platelet function in baboons and humans — A comparative study of whole blood using impedance platelet aggregometry (Multiplate®). Thrombosis Research. 147. 115–121. 3 indexed citations

Xu, Yifan, et al.. (2015). Acute Efficacy of a Novel Anti-Tissue Factor Pathway Inhibitor Antibody BAY 1093884 in Hemophilia A Mouse Severe Tail Bleeding. Blood. 126(23). 3500–3500. 1 indexed citations

Ramsey, Patrick S., Liang Tang, Heiner Apeler, et al.. (2014). Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94‐9027) for haemophilia A. Haemophilia. 20(4). 593–600. 62 indexed citations

10.

Perzborn, Elisabeth, Stefan Heitmeier, Ulf Buetehorn, & Volker Laux. (2014). Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor‐induced hypercoagulability in vitro and in vivo. Journal of Thrombosis and Haemostasis. 12(7). 1054–1065. 54 indexed citations

11.

Perzborn, Elisabeth, et al.. (2014). Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thrombosis Research. 133(4). 671–681. 86 indexed citations

12.

Becker, E., et al.. (2012). Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis. Journal of Thrombosis and Haemostasis. 10(12). 2470–2480. 25 indexed citations

13.

Viskov, Christian, Melitta Just, Volker Laux, Pierre Mourier, & M. Lorenz. (2009). Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra‐low‐molecular‐weight heparin, AVE5026. Journal of Thrombosis and Haemostasis. 7(7). 1143–1151. 50 indexed citations

14.

Perzborn, Elisabeth, Stefan Heitmeier, Georges von Degenfeld, et al.. (2009). Direct inhibitors of coagulation proteins – the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?. Thrombosis and Haemostasis. 102(11). 892–899. 49 indexed citations

15.

Laux, Volker, Elisabeth Perzborn, Dagmar Kubitza, & Frank Misselwitz. (2007). Preclinical and Clinical Characteristics of Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor. Seminars in Thrombosis and Hemostasis. 33(5). 515–523. 58 indexed citations

16.

Nazaré, Marc, Hans Matter, Otmar Klingler, et al.. (2004). Novel factor Xa inhibitors based on a benzoic acid scaffold and incorporating a neutral P1 ligand. Bioorganic & Medicinal Chemistry Letters. 14(11). 2801–2805. 11 indexed citations

17.

Nazaré, Marc, David W. Will, Hans Matter, et al.. (2004). Factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of neutral P1 substituents. Bioorganic & Medicinal Chemistry Letters. 14(16). 4191–4195. 13 indexed citations

18.

Nazaré, Marc, David W. Will, Hans Matter, et al.. (2004). Novel factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of P4 substituents in combination with a neutral P1 ligand. Bioorganic & Medicinal Chemistry Letters. 14(16). 4197–4201. 14 indexed citations

19.

Seiffge, D., et al.. (1995). Inhibitory effects of pentoxifylline on LPS-induced leukocyte adhesion and macromolecular extravasation in the microcirculation. Inflammation Research. 44(7). 281–286. 20 indexed citations

20.

Laux, Volker & D. Seiffge. (1995). Mediator-Induced Changes in Macromolecular Permeability in the Rat Mesenteric Microcirculation. Microvascular Research. 49(1). 117–133. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact